For the second quarter of 2026, analysts expect Eupraxia Pharmaceuticals to report a consensus loss per share of $0.25 on zero revenue, with the current stock price of $6.59 trading significantly below the average analyst price target of $16.28.
Investors are primarily focused on clinical updates regarding the lead product candidate, EP-104GI, particularly progress in the RESOLVE Phase 2b trial for Eosinophilic Esophagitis. The company recently strengthened its board and leadership team to support upcoming Phase 3 development and commercialization efforts.
With a cash position of approximately $84.6 million, the market is closely evaluating Eupraxia’s runway as it nears pivotal interim data releases scheduled for late 2026.